to provide effective, accessible, scalable treatment for covid-19 | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2020
Known Financial Commitments (USD)
$3,268,572
Funder
Gates Foundation
Research Location
United States of America
Lead Research Institution
University of Minnesota
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

N/A

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.

Authors
Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, Buse JB, Johnson DM, Watson RHB, Daniel JJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Anderson B, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Fricton RD, Lee S, Griffiths G, Pullen MF, Thompson JL, Sherwood NE, Murray TA, Rose MR, Boulware DR, Huling JD, COVID-OUT Study Team.
Publish Year
2024
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DOI
10.1093/cid/ciae159

View at Europe PMC

Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers.